In pretty early.
IN that Gateway Pundit article, the original study is linked here:
At the link, there’s an introduction, then a walk through of Vitamin C, D3, Zinc, Fenbendazole, Membendazole and other supplements and how they destroy cancer cells. Personally, if I could not pull together everything on the list quickly, I might take what I had available to glean as much benefit as possible until I could take the entire protocol - that's just me.
Then there is a section titled, Proposed Orthomolecular Protocol.
I will paste that protocol excerpt below. It’s the first detailed protocol I've seen for cancer invovling supplments and Ivermectin; it dosage and how many days per week, and how many weeks.
The Vitamin C in the protocol is intraveneous, but if you can’t get that by asking your doc, and showing him C helps (some documentation - maybe not this article) then you might investigate to find out if liposomal Vitamin C might be beneficial. Liiposomal C by passes the stomach. so no stomach upset. I don’t know what brands are ‘good’ because I cringe at the use of liposomes for anything after they made the vax in liposomal pouches! Dr. Mercola has a liposomal C. But let’s say ‘as much C as possible, if you can't get a prescription or aren't able to simply pay for C infusions.
The whole study document was highly informative as it described what each supplement did to combat cancer. The protocol proposes 12 weeks of treatment.
____PROPOSED CANCER PROTOCOL
Proposed Hybrid Orthomolecular Protocol
Based on our review of the scientific literature, the following protocol combining orthomolecules, drugs and additional therapies for targeting the MSCC in cancer treatment is proposed:
Intravenous Vitamin C
Intermediate- and high-grade cancers: Dose of 1.5g/kg/day, 2-3x per week (Fan, et al., 2023).
Established as a non-toxic dose for cancer patients (Wang, F., et al., 2019).
.
Oral Vitamin D
All cancer grades: Dose of 50,000 IU/day for patients with a blood level ≤ 30ng/mL; 25,000 IU/day for levels 30-60ng/mL; and 5000 IU/day for levels 60-80ng/mL.
Established as a non-toxic dose (Cannon, et al., 2016; Ghanaati, et al., 2020; McCullough, et al., 2019).
It is necessary to reach a blood level of 80 ng/mL of vitamin D (25-hydroxyvitamine D (25(OH) D) (Kennel, et al., 2010; Mohr, et al., 2014; Mohr, et al., 2015). This level is non-toxic (Holick, et al., 2011). Once this level is reached it must be maintained with a reduced daily dosage of ≈ 2000 IU/day (Ekwaru, et al., 2014). The vitamin D blood concentration should be measured every two weeks for high doses and monthly for lower doses.
.
Zinc
All cancer grades: Dose of 1 mg/kg/day is established as a non-toxic dose for cancer patients (Hoppe, et al., 2021; Lin, et al., 2006). The reference range for serum zinc concentration is 80 to 120 μg/dL (Mashhadi, et al., 2016; Yokokawa, et al., 2020). Once this level is reached it must be maintained with a reduced daily dosage of 5mg/day (Li, et al., 2022). The zinc blood concentration should be measured monthly.
.
Ivermectin
Low-grade cancers: Dose of 0.5mg/kg, 3x per week (Guzzo, et al., 2002).
Intermediate-grade cancers: Dose of 1mg/kg, 3x per week (Guzzo, et al., 2002).
High-grade cancers: Dose from 1 mg/kg/day (de Castro, et al., 2020) to 2 mg/kg/day (Guzzo, et al., 2002).
All these doses have been established as tolerable for humans (Guzzo, et al., 2002).
.
Benzimidazoles and DON
Low-grade cancers: Mebendazole: Dose of 200 mg/day (Dobrosotskaya, et al., 2011).
Intermediate-grade cancers: Mebendazole: Dose of 400 mg/day (Chai, et al., 2021).
High-grade cancers: Mebendazole dose of 1,500 mg/day (Son, et al., 2020) or Fenbendazole 1,000 mg 3x per week (Chiang, et al., 2021).
All these doses have been established as tolerable for humans (Chai, et al., 2021; Chiang, et al., 2021; Son, et al., 2020). Benzimidazoles can be replaced or combined with DON, administered without toxicity; intravenously or intramuscularly: 0.2 to 0.6 mg/kg once daily; or orally: 0.2 to 1.1 mg/kg once daily (Lemberg, et al., 2018; Rais, et al., 2022). Benzimidazoles are much easier to obtain than DON. However, for metastatic cancers, which rely heavily on glutamine (Seyfried, et al., 2020), a combination of DON and Benzimidazoles should be considered (Mukherjee, et al., 2023).
.
Dietary Interventions
All cancer grades: Ketogenic diet (low carbohydrate-high fat diet, 900 to 1500 kcal/day) (Weber, et al., 2020).
Ketone metabolic therapy consists of approximately 60-80% fat, 15-25% protein and 5-10% fibrous carbohydrates. Adequate hydration and single-ingredient whole food ketogenic meals are necessary to achieve a glucose ketone index (GKI) score of 2.0 or below (Meidenbauer, et al., 2015; Seyfried, Shivane, et al., 2021). GKI should be measured 2–3 hours postprandial, twice a day if possible (Meidenbauer, et al., 2015; Seyfried, Shivane, et al., 2021).
Intermediate- and high-grade cancers: The ketogenic diet should be coupled with a water fast for 3 to 7 consecutive days in advanced cancers (Phillips, et al., 2022; Arora, et al., 2023). The water fast should be repeated several times (≈ every 3-4 weeks) throughout the treatment (Nencioni, et al., 2018), but fasting needs to be undertaken cautiously in individuals using certain drugs and those with < 20 BMI, to prevent loss of lean body mass. For patients who can not fast, the Fasting-Mimicking Diet (300 to 1,100 kcal/day of broths, soups, juices, nut bars, and herbal teas) can be used (Nencioni, et al., 2018).
.
Additional Therapeutics
All cancer grades: Moderate physical activity, 3x per week. Increased heart and respiratory rate for a period of 45 to 75 minutes (Bull, et al., 2020) with activities such as cycling, running, swimming, etc.
Intermediate- and high-grade cancers or individuals who are unable to engage in physical activity: Hyperbaric oxygen therapy, 1.5 to 2.5 ATA for 45 to 60 minutes 2-3x per week (Gonzalez, et al., 2018; Poff, et al., 2015).
The protocol should be followed for an average duration of 12 weeks, regardless of cancer type. The analysis of the interactions between each of the molecules revealed no contraindications to the combination of these substances (ANSM, 2023; CRAT, 2024; Lemberg, et al., 2018; Vidal, 2024). The treatment dosage and duration can be adjusted by the physician according to the individual patient, their ability to obtain the various molecules, and the treatment results. Adaptation of the protocol to include additional molecules to restore health, could be considered by the physician. These may include: vitamin K2 (Xv, et al., 2018), vitamin E (Abraham, et al., 2019), coenzyme Q10 (Liaghat, et al., 2024), methylene blue (da Veiga Moreira, et al., 2024), niacinamide (Yousef, et al., 2022), riboflavin (Suwannasom, et al., 2020), Artemisinin + 5-aminolevulinic acid (to cause porphyrin accumulation) (Adapa, et al., 2024), melatonin (Mocayar, et al., 2020), NADH (Medjdoub, et al., 2016), and magnesium (Ashique, et al., 2023), as examples. However, antioxidant dosages should be avoided.
This additive and synergistic effect of this combination of orthomolecules, drugs, and additional therapies targets the MSCC by increasing OxPhos activity in healthy mitochondria, offering protective action for these cells. However, in cancer cells, both CSCs and non-CSCs, the pro-oxidant effect of the combination induces apoptosis. Additionally, this protocol specifically targets fermentable fuels, CSCs and macrophages, and thus metastases. In brief, the key points of the MSCC. Therefore, comparative studies need to be conducted in both animals and humans to evaluate the effectiveness and safety of this hybrid protocol against standard therapies.